3. Segment Information and Concentrations

9 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Segment Information and Concentrations

The Company views its operations as three segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors ("Benchtop Laboratory Equipment"), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis ("Catalyst Research Instruments") and the marketing and production of bioprocessing systems for laboratory research in the biotechnology industry sold directly to customers and through distributors ("Bioprocessing Systems").

Segment information is reported as follows (foreign sales are principally to customers in Europe and Asia):

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems		Corporate and Other		Consolidated
Three months ended March 31, 2017:
Revenues	$	1,410,800	$	359,800		$	140,300	$	—	$	1,910,900
Foreign Sales		611,400		37,100			—		—		648,500
Income (Loss) from Operations		88,900		(82,400	)		76,500		—		83,000
Assets		4,170,900		1,822,200			485,700		719,200		7,198,000
Long-Lived Asset Expenditures		4,600		—			7,000		—		11,600
Depreciation and Amortization		73,500		1,600			12,000		—		87,100

		Benchtop Laboratory Equipment		Catalyst Research Instruments		Bioprocessing Systems			Corporate and Other			Consolidated
Three months ended March 31, 2016:
Revenues	$	1,279,300	$	364,900	$	30,100		$	—		$	1,674,300
Foreign Sales		597,300		25,900		—			—			623,200
Income (Loss) from Operations		2,800		5,500		(29,600	)		(13,800	)		(35,100	)
Assets		4,358,700		2,898,400		746,200			595,000			8,598,300
Long-Lived Asset Expenditures		31,500		3,200		3,700			—			38,400
Depreciation and Amortization		74,800		9,000		24,500			—			108,300

Approximately 54% and 50% of net sales of benchtop laboratory equipment for the three month periods ended March 31, 2017 and 2016, respectively, were derived from the Company's main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 21% and 22% of total benchtop laboratory equipment sales were derived from the Torbal Scales Division for the three months ended March 31, 2017 and 2016, respectively.

Two benchtop laboratory equipment customers accounted for approximately 15% and 19% of the segment's net sales for the three month periods ended March 31, 2017 and 2016 (11% and 15% of total revenues, respectively, for the periods).

Sales of catalyst research instruments are generally pursuant to large orders averaging more than $100,000 per order to a limited numbers of customers. Sales to two customers in the three months ended March 31, 2017 and two different customers in the three months ended March 31, 2016, accounted respectively for 76% and 86% of the segment's net sales for each of the periods (14% and 19% of total revenues, respectively, for the periods).

		Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems		Corporate and Other		Consolidated
Nine months ended March 31, 2017:
Revenues	$	4,334,400	$	1,629,400		$	190,000	$	—	$	6,153,800
Foreign Sales		1,924,400		52,200			—		—		1,976,600
Income (Loss) from Operations		252,900		(197,400	)		9,100		—		64,600
Assets		4,170,900		1,822,200			485,700		719,200		7,198,000
Long-Lived Asset Expenditures		18,200		—			12,800		—		31,000
Depreciation and Amortization		226,800		12,700			37,000		—		276,500

		Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems			Corporate and Other			Consolidated
Nine months ended March 31, 2016:
Revenues	$	4,125,900	$	932,300		$	88,700		$	—		$	5,146,900
Foreign Sales		1,960,700		139,200			—			—			2,099,900
Income (Loss) from Operations		245,200		(86,700	)		(92,500	)		(35,900	)		30,100
Assets		4,358,700		2,898,400			746,200			595,000			8,598,300
Long-Lived Asset Expenditures		39,900		3,200			9,400			—			52,500
Depreciation and Amortization		222,800		22,900			73,400			—			319,100

Approximately 53% and 50% of net sales of benchtop laboratory equipment for the nine month periods ended March 31, 2017 and 2016,respectively, were derived from sales of the Company's main product, the Vortex-Genie 2 mixer, excluding accessories. 7 Approximately 23% and 21% of total benchtop laboratory equipment sales for the nine months ended March 31, 2017 and 2016, respectively, were derived from sales of the Torbal Scales Division.

Two benchtop laboratory equipment customers, accounted for approximately 11% and 15% of the segment's net sales (% and 12% of total revenues) for the nine month periods ended March 31, 2017 and 2016, respectively.

Sales of catalyst research instruments to four customers in the nine months ended March 31, 2017 and to four other customers in the nine months ended March 31, 2016 accounted for approximately 92% and 87% of that segment's net sales (24% and 16% of total revenues) for the respective nine month periods.

The Company's foreign sales are principally made to customers in Europe and Asia. The Company also has an arrangement with a supplier for annual minimum purchase commitments through February 2020 which the Company has already met for the current year.